Gilead Swings to Profit, Names CFO
Gilead(GILD Quote) reported a 3-cent earnings beat, strong HIV franchise sales and a new CFO after Thursday's market close.
Net income for the third quarter was $398.3 million, or 42 cents a diluted share, including after-tax stock-based compensation expenses of $31.8 million, compared to a loss of 3 cents in the year-ago quarter. Analysts surveyed by Thomson Financial expected 39 cents a share on revenue of $1 billion. Gilead reported total revenue of $1.1 billion and HIV product sales of $805.8 million in the third quarter of 2007, a 45% increase from $557.3 million for the same period in 2006. The increase was driven primarily by the sales volume growth in Truvada and Atripla (a single-pill combination of Truvada with Bristol-Myers Squibb's(BMY Quote) Sustiva), and beat the Street consensus of $954 million for total product sales and $794 million for the HIV franchise. Truvada sales were $409.1 million in the recent quarter (beating Street estimates of $390 million), an increase of 32% from $309 million in the third quarter of 2006. Truvada sales accounted for roughly 51% of Gilead's total HIV product sales and about 43% of the company's total product sales in the third quarter of 2007. Atripla sales came in at $241.1 million (just lighter than the Street consensus of $241 million), compared to $68.4 million recorded in the third quarter of 2006, the drug's first quarter of sales in the U.S. Viread (also for HIV) sales increased 13% to $149.1 million.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,452.61 | 1,106.36 | 2,192.95 | 35.75 |
Oil *
71.76
|
|
UP
46.78
|
UP
4.01
|
UP
2.09
|
UP
0.93
|
10 Yr
3.57%
SPDR Gold
109.66
|
|
+0.45%
|
+0.36%
|
+0.10%
|
+2.67%
|
Data delayed 20 minutes |














